Dequidt T, Bastian S, Nacher M, Breurec S, Carles M, Thiery G
Crit Care. 2023; 27(1):418.
PMID: 37915017
PMC: 10619259.
DOI: 10.1186/s13054-023-04712-2.
Ito R, Kawamura M, Sato T, Fujimura S
Infect Drug Resist. 2022; 15:5867-5878.
PMID: 36237294
PMC: 9553235.
DOI: 10.2147/IDR.S382142.
Montiel-Riquelme F, Calatrava-Hernandez E, Gutierrez-Soto M, Exposito-Ruiz M, Navarro-Mari J, Gutierrez-Fernandez J
Microorganisms. 2020; 8(10).
PMID: 33050170
PMC: 7601678.
DOI: 10.3390/microorganisms8101555.
Senard O, Lafaurie M, Lesprit P, Nguyen Y, Lescure X, Therby A
Eur J Clin Microbiol Infect Dis. 2019; 39(1):121-129.
PMID: 31512147
DOI: 10.1007/s10096-019-03701-0.
Senard O, Bouchand F, Deconinck L, Matt M, Fellous L, Rottman M
Ther Adv Infect Dis. 2019; 6:2049936118811053.
PMID: 30891241
PMC: 6416675.
DOI: 10.1177/2049936118811053.
Interplay Between Membrane Permeability and Enzymatic Barrier Leads to Antibiotic-Dependent Resistance in .
Nicolas-Chanoine M, Mayer N, Guyot K, Dumont E, Pages J
Front Microbiol. 2018; 9:1422.
PMID: 30008709
PMC: 6034560.
DOI: 10.3389/fmicb.2018.01422.
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A
Clin Microbiol Rev. 2018; 31(2).
PMID: 29444952
PMC: 5967687.
DOI: 10.1128/CMR.00079-17.
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Tamma P, Rodriguez-Bano J
Clin Infect Dis. 2017; 64(7):972-980.
PMID: 28362938
PMC: 5848369.
DOI: 10.1093/cid/cix034.
Klebsiella pneumoniae Major Porins OmpK35 and OmpK36 Allow More Efficient Diffusion of β-Lactams than Their Escherichia coli Homologs OmpF and OmpC.
Sugawara E, Kojima S, Nikaido H
J Bacteriol. 2016; 198(23):3200-3208.
PMID: 27645385
PMC: 5105900.
DOI: 10.1128/JB.00590-16.
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.
Li X, Plesiat P, Nikaido H
Clin Microbiol Rev. 2015; 28(2):337-418.
PMID: 25788514
PMC: 4402952.
DOI: 10.1128/CMR.00117-14.
Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.
Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O
Antimicrob Agents Chemother. 2014; 58(8):4899-901.
PMID: 24777104
PMC: 4135984.
DOI: 10.1128/AAC.02509-14.
Incidence of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in patients with urinary tract infection.
Ghafourian S, Sekawi Z, Neela V, Khosravi A, Rahbar M, Sadeghifard N
Sao Paulo Med J. 2012; 130(1):37-43.
PMID: 22344358
PMC: 10906682.
DOI: 10.1590/s1516-31802012000100007.
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A
Antimicrob Agents Chemother. 2012; 56(3):1376-81.
PMID: 22214774
PMC: 3294923.
DOI: 10.1128/AAC.06233-11.
Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.
Pitout J
Drugs. 2010; 70(3):313-33.
PMID: 20166768
DOI: 10.2165/11533040-000000000-00000.
Prevalence of AmpC and other beta-lactamases in enterobacteria at a large urban university hospital in Brazil.
Dias R, Borges-Neto A, Ferraiuoli G, de-Oliveira M, Riley L, Moreira B
Diagn Microbiol Infect Dis. 2007; 60(1):79-87.
PMID: 17900845
PMC: 2894158.
DOI: 10.1016/j.diagmicrobio.2007.07.018.
Extended-spectrum beta-lactamases: a clinical update.
Paterson D, Bonomo R
Clin Microbiol Rev. 2005; 18(4):657-86.
PMID: 16223952
PMC: 1265908.
DOI: 10.1128/CMR.18.4.657-686.2005.
Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae.
Schwaber M, Raney P, Rasheed J, Biddle J, Williams P, McGowan Jr J
J Clin Microbiol. 2004; 42(1):294-8.
PMID: 14715768
PMC: 321707.
DOI: 10.1128/JCM.42.1.294-298.2004.
Molecular basis of bacterial outer membrane permeability revisited.
Nikaido H
Microbiol Mol Biol Rev. 2003; 67(4):593-656.
PMID: 14665678
PMC: 309051.
DOI: 10.1128/MMBR.67.4.593-656.2003.
Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.
Rupp M, Fey P
Drugs. 2003; 63(4):353-65.
PMID: 12558458
DOI: 10.2165/00003495-200363040-00002.
Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland.
Baraniak A, Fiett J, Sulikowska A, Hryniewicz W, Gniadkowski M
Antimicrob Agents Chemother. 2001; 46(1):151-9.
PMID: 11751126
PMC: 126981.
DOI: 10.1128/AAC.46.1.151-159.2002.
